randomisation codes (Janssen)
Structured Review
Randomisation Codes, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisation+code/codes+randomisation/pmc11536474-399-20-25
Average 86 stars, based on 1 article reviews
Images
Related Articles
Magnetic Resonance Imaging:Article Title: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Article Snippet: .. Other bias Low risk No other sources of bias Black 2003 (Continued) Study characteristics Methods Randomised, placebo-controlled, multicentre, double-blind trial of 6 months duration Participants 592 participants with probable vascular dementia or Alzheimer’s disease combined with CVD (NINDSAIREN or NINCDS-ADRDA criteria plus significant radiological evidence of CVD on CT or MRI); mean age 75.1 years, 53% male participants Interventions Galantamine (24 mg/day) versus placebo for 6 months Outcomes ADAS-Cog/11, CIBIC-Plus, ADAS-Cog/13, DAD, NPI, adverse events Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "...patients were randomly assigned placebo or galantamine 24 mg/ day for 6 months according to a Sequencing:Article Title: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Article Snippet: .. Other bias Low risk No other sources of bias Black 2003 (Continued) Study characteristics Methods Randomised, placebo-controlled, multicentre, double-blind trial of 6 months duration Participants 592 participants with probable vascular dementia or Alzheimer’s disease combined with CVD (NINDSAIREN or NINCDS-ADRDA criteria plus significant radiological evidence of CVD on CT or MRI); mean age 75.1 years, 53% male participants Interventions Galantamine (24 mg/day) versus placebo for 6 months Outcomes ADAS-Cog/11, CIBIC-Plus, ADAS-Cog/13, DAD, NPI, adverse events Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "...patients were randomly assigned placebo or galantamine 24 mg/ day for 6 months according to a Selection:Article Title: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Article Snippet: .. Other bias Low risk No other sources of bias Black 2003 (Continued) Study characteristics Methods Randomised, placebo-controlled, multicentre, double-blind trial of 6 months duration Participants 592 participants with probable vascular dementia or Alzheimer’s disease combined with CVD (NINDSAIREN or NINCDS-ADRDA criteria plus significant radiological evidence of CVD on CT or MRI); mean age 75.1 years, 53% male participants Interventions Galantamine (24 mg/day) versus placebo for 6 months Outcomes ADAS-Cog/11, CIBIC-Plus, ADAS-Cog/13, DAD, NPI, adverse events Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "...patients were randomly assigned placebo or galantamine 24 mg/ day for 6 months according to a Generated:Article Title: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Article Snippet: .. Other bias Low risk No other sources of bias Black 2003 (Continued) Study characteristics Methods Randomised, placebo-controlled, multicentre, double-blind trial of 6 months duration Participants 592 participants with probable vascular dementia or Alzheimer’s disease combined with CVD (NINDSAIREN or NINCDS-ADRDA criteria plus significant radiological evidence of CVD on CT or MRI); mean age 75.1 years, 53% male participants Interventions Galantamine (24 mg/day) versus placebo for 6 months Outcomes ADAS-Cog/11, CIBIC-Plus, ADAS-Cog/13, DAD, NPI, adverse events Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote: "...patients were randomly assigned placebo or galantamine 24 mg/ day for 6 months according to a |
Anthenelli 2016 " width="250" height="auto" />
Berlin 1995 " width="100%" height="100%">
Blondal 1999 " width="100%" height="100%">
Dalsgarð 2004 " width="100%" height="100%">
Evins 2001 " width="100%" height="100%">
Evins 2005 " width="100%" height="100%">
Evins 2007 " width="100%" height="100%">
Ferry 1992 " width="100%" height="100%">
Ferry 1994 " width="100%" height="100%">
Fossati 2007 " width="100%" height="100%">
George 2002 " width="100%" height="100%">
George 2003 " width="100%" height="100%">
George 2008 " width="100%" height="100%">
Grant 2007 " width="100%" height="100%">
Górecka 2003 " width="100%" height="100%">
Haggsträm 2006 " width="100%" height="100%">
Hall 1998 " width="100%" height="100%">
Hall 2004 " width="100%" height="100%">
Hertzberg 2001 " width="100%" height="100%">
Holt 2005 " width="100%" height="100%">
Killen 2004 " width="100%" height="100%">
Levine 2010 " width="100%" height="100%">
Parsons 2009 " width="100%" height="100%">
Prochazka 1998 " width="100%" height="100%">
Saules 2004 " width="100%" height="100%">
Selby 2003 " width="100%" height="100%">
Siddiqi 2013 " width="100%" height="100%">
SMK20001 " width="100%" height="100%">
Tashkin 2001 " width="100%" height="100%">
Tonstad 2003 " width="100%" height="100%">
Weinberger 2010 " width="100%" height="100%">
Wittchen 2011 " width="100%" height="100%">
Zellweger 2005 " width="100%" height="100%">